Carbamazepine population pharmacokinetics in children: mixed-effect models

Area of Science:

• Pharmacokinetics
• Pediatric Epilepsy
• Drug Metabolism

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug in children.
• Understanding factors influencing CBZ clearance is crucial for optimizing pediatric dosing and therapeutic outcomes.
• Previous studies have shown variability in CBZ pharmacokinetics among pediatric populations.

Purpose of the Study:

• To investigate the impact of various factors on carbamazepine (CBZ) clearance (CL) in children with epilepsy.
• To develop and validate a population pharmacokinetic model for CBZ in pediatric patients.
• To provide a basis for accurate CBZ dosage recommendations in children.

Main Methods:

• Analysis of 387 steady-state serum CBZ concentration samples from 201 children (aged 1-14 years).
• Utilized NONMEM software with a one-compartment model for population CL calculation.
• Evaluated total body weight (TBW), age, dose, sex, and comedications (phenobarbital [PB], valproic acid [VA]) as covariates.

Main Results:

• CBZ CL increased linearly with TBW and nonlinearly with age.
• CBZ CL also increased with dose, suggesting dose-dependent autoinduction.
• Concomitant PB administration significantly affected CL, while sex and VA did not.

Conclusions:

• A validated population pharmacokinetic model accurately predicts CBZ CL in children.
• The model highlights the importance of TBW, age, dose, and PB comedication for pediatric CBZ dosing.
• The findings support the development of precise CBZ dosage guidelines for pediatric epilepsy management.